Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eravacycline versus moxifloxacin for community-acquired bacterial pneumonia
ChiCTR2200055666Phase 3Recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Jul 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of eravacycline and moxifloxacin in community acquired pneumonia (CAP) (4 arms), sponsored by China-Japan Friendship Hospital. Primary endpoint: Clinical efficacy. Started Jul 2021; status: recruiting.
02
Drugs
eravacyclinemoxifloxacin
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on ChiCTR2200055666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055666.